RxDoctor Payments Data

Silvio Papapietro

Interventional Cardiology · Birmingham, ALNPI 1467483933

Payments from drug & device makers

$763in general payments, 2019–2025

Across 47 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$324
  • Merck$71
  • Amgen$68
  • Abbott$67
  • Pfizer$64
  • Boehringer Ingelheim$37
  • plus $132 from 7 others

What the payments were for

  • Food & beverage$763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$763 in reported general payments places this provider in the 5th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$86,468
Medicare patients
367
Services billed
1,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan178$193,420
EliquisApixaban177$169,272
Repatha SureclickEvolocumab69$46,370
XareltoRivaroxaban40$34,188
JardianceEmpagliflozin35$28,619
NexlizetBempedoic Acid/Ezetimibe14$15,899
FarxigaDapagliflozin Propanediol12$12,629
Clonidine47$9,876
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide106$4,361
Ezetimibe122$4,345
Metoprolol Succinate193$3,854
Atorvastatin Calcium251$3,828
Potassium Chloride152$3,721
Eplerenone28$3,462
Valsartan79$3,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$324$193,420178 claims
PfizerEliquis$64$169,272177 claims
Johnson & JohnsonXarelto$15$34,18840 claims
Boehringer IngelheimJardiance$37$28,61935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →